Sai Parenteral's Limited share price

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

• Sai Parenteral's Limited is in the Drug Manufacturers - General industry (Healthcare), with a market value of ₹2,153 crore.
• It trades at 168.0 times its last 12 months' earnings and 3.2 times book value.
• Revenue grew 126.1% a year over the last 2 years, profit 111.8% a year.
• Return on equity was 21.1% and return on capital employed 17.9% in the latest year.
• Debt was 1.83 times shareholders' equity.
• The share price is 31.0% below its 52-week high.
• Promoters and insiders hold about 74.8%; institutions about 9.6%.

Sai Parenteral's Limited, a pharmaceutical formulations company, engages in the branded generic formulations and contract development and manufacturing businesses in India and internationally. Its portfolio includes formulation products across various therapeutic areas, such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, oncology, and dermatology in various dosage forms, including injectables, solid orals, liquid orals, and topicals. The company was founded in 1988 and is based in Hyderabad, India.

Employees

293

Head office

Hyderabad

HealthcareDrug Manufacturers - General

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Consolidated figures in ₹ crore / View Standalone

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Consolidated figures in ₹ crore / View Standalone

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Consolidated figures in ₹ crore, as at 31 March

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Consolidated figures in ₹ crore, financial years ending March

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Numbers in percentages · as filed with NSE each quarter

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Filings made by the company with NSE; documents open on NSE's website.

Ex-dividend date

1 Jan 1970

Latest quarter

30 Jun 2026

Financial year end

31 Mar 2026

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.